Preclinical pharmacology of the MDM2 antagonist nutlin-3a

@inproceedings{Zhang2011PreclinicalPO,
  title={Preclinical pharmacology of the MDM2 antagonist nutlin-3a},
  author={F. R. Zhang},
  year={2011}
}

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 263 REFERENCES

Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2011
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2006
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Physiologically-based pharmacokinetics in drug development and regulatory science.

  • Annual review of pharmacology and toxicology
  • 2011
VIEW 18 EXCERPTS
HIGHLY INFLUENTIAL

Membrane transporters in drug development

  • Nature Reviews Drug Discovery
  • 2010
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion

  • Journal of Pharmacokinetics and Pharmacodynamics
  • 2010
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53

T Van Maerken
  • Journal of the National Cancer Institute,
  • 2009
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL